Findings from an echocardiographic study of patients with heart failure with preserved or mildly reduced ejection fraction treated with an atrial shunt have shed more light on mechanisms that explain ...

ATLANTA -- An interatrial shunt failed to provide a clinical benefit to people with heart failure (HF) overall in the RELIEVE-HF trial, though actual harm or benefit seemed to hinge on the patient's ...

There is a persistent lack of effective treatments for heart failure with preserved ejection fraction (HFpEF), so in this study, investigators examined the impact of an atrial shunt among patients ...

Please provide your email address to receive an email when new articles are posted on . Interatrial shunt implant lowered HF hospitalization risk for patients with HFrEF vs. placebo. However, patients ...

Placement of an atrial shunt device intended to reduce pulmonary capillary wedge pressure (PCWP) during exercise in patients with heart failure and preserved ejection fraction (HFpEF) does not reduce ...

A differential effect of atrial shunt device treatment on heart failure events was seen in prespecified subgroups of pulmonary artery systolic pressure at 20W of bicycle exercise, right atrial volume ...

Patients who responded positively to shunt treatment experienced more beneficial changes in their heart's structure and function compared with nonresponders. After 2 years of follow-up, a post hoc ...

Inter-atrial shunts—investigational devices that create a small pathway for blood to pass from the left to the right side of the heart in order to improve heart failure symptoms and outcomes—may be ...

Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced results from its REDUCE LAP-HF II randomized clinical trial, investigating the safety and ...

Texas-based medical device company Alleviant has received a breakthrough device status from the US Food and Drug Administration (FDA) for its new no-implant atrial shunt for heart failure and will ...

Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced results from its REDUCE LAP-HF II randomized clinical trial, investigating the safety and ...